Cypress Bioscience Prosorba Rheumatoid Arthritis Trial Gets HCFA Nod
This article was originally published in The Gray Sheet
Executive Summary
Unpublished information generated in Cypress Bioscience's Prosorba clinical trial for rheumatoid arthritis was instrumental in the Health Care Financing Administration's decision to cover treatment for the Medicare population.
You may also be interested in...
Cypress Eyeing $200-400 Mil. Prosorba Sales Based On 1-2% Of RA Market
Cypress Bioscience expects its Prosorba column for treatment of rheumatoid arthritis to be a $200-400 mil. product by 2003, the company said following FDA's premarket approval of the device March 16. The PMA was submitted last July.
Adalvo Hails First European Launch Of Prolonged-Release Pregabalin
After the drug’s approval for use in neuropathic pain within the EU last December, Adalvo announced the analgesic’s first European launch in Germany.
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.